Related references
Note: Only part of the references are listed.CXCL 10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation
Karen P. Piper et al.
BLOOD (2007)
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Agnes S. M. Yong et al.
BLOOD (2007)
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
Mohamad Mohty et al.
BLOOD (2007)
Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3
Hiroyuki Hosokawa et al.
JOURNAL OF IMMUNOLOGY (2006)
The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens
J. C. Steele et al.
BRITISH JOURNAL OF CANCER (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Molecular profiling of CD34(+) cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
ASM Yong et al.
BLOOD (2006)
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
K Mihara et al.
BLOOD (2006)
Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
M Mohty et al.
BLOOD (2005)
The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins
JH Kim et al.
CANCER LETTERS (2004)
Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants
JR Passweg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
JJ Molldrem et al.
NATURE MEDICINE (2000)
Share Paper
